Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -58.45% is 13% below its 5-year average of -51.62%, near the high end of its 5-year range (-134.12%–-27.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.98% below its 12-month average of -57.88%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -58.45%.
RETURN ON EQUITY (ROE)
-58.45%
RETURN ON EQUITY (ROE) AVG TTM
-57.88%
RETURN ON EQUITY (ROE) AVG 3Y
-53.10%
RETURN ON EQUITY (ROE) AVG 5Y
-51.62%
RETURN ON EQUITY (ROE) AVG 10Y
-73.85%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.98%
CURRENT VS 3Y AVG
-10.07%
CURRENT VS 5Y AVG
-13.22%
CURRENT VS 10Y AVG
+20.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-39.13%
vs the sector median at left
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Return on Equity (ROE)
-58.45%
TTM Avg
-57.88%
3Y Avg
-53.10%
5Y Avg
-51.62%
Market Cap
$2.06B
Return on Equity (ROE)
-42.07%
TTM Avg
-35.11%
3Y Avg
-34.40%
5Y Avg
-30.49%
Market Cap
$2.05B
Return on Equity (ROE)
6.55%
TTM Avg
4.11%
3Y Avg
-0.47%
5Y Avg
-0.69%
Market Cap
$2.03B
Return on Equity (ROE)
17.35%
TTM Avg
12.11%
3Y Avg
10.87%
5Y Avg
16.24%
Market Cap
$2.02B
Return on Equity (ROE)
N/A
TTM Avg
-101.38%
3Y Avg
-17.29%
5Y Avg
175.33%
Market Cap
$2.11B
Return on Equity (ROE)
-23.58%
TTM Avg
-182.08%
3Y Avg
-186.85%
5Y Avg
-151.51%
Market Cap
$2.02B
Return on Equity (ROE)
N/A
TTM Avg
793.39%
3Y Avg
466.61%
5Y Avg
69.31%
Market Cap
$2.02B
Return on Equity (ROE)
51.09%
TTM Avg
25.46%
3Y Avg
0.90%
5Y Avg
-9.89%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | -58.45% | -57.88% | -53.10% | -51.62% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -42.07% | -35.11% | -34.40% | -30.49% |
| Alvotech (ALVO)vs › | $2.08B | N/A | 23.18% | 49.13% | 48.50% |
| Vericel Corporation (VCEL)vs › | $2.05B | 6.55% | 4.11% | -0.47% | -0.69% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 17.35% | 12.11% | 10.87% | 16.24% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | -101.38% | -17.29% | 175.33% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -23.58% | -182.08% | -186.85% | -151.51% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 793.39% | 466.61% | 69.31% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 51.09% | 25.46% | 0.90% | -9.89% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | -98.56% | -37.96% | -71.53% | -45.53% |
ROE
-58.4%
ROA
-35.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -58.45% |
| 2026-03-31 | -56.70% |
| 2025-12-31 | -47.44% |
| 2025-09-30 | -60.04% |
| 2025-06-30 | -66.79% |
| 2025-03-31 | -51.01% |
| 2024-12-31 | -40.19% |
| 2024-09-30 | -36.34% |
| 2024-06-30 | -43.08% |
| 2024-03-31 | -37.44% |
| 2023-12-31 | -53.78% |
| 2023-09-30 | -76.40% |
| 2023-06-30 | -62.66% |
| 2023-03-31 | -49.16% |
| 2022-12-31 | -32.87% |
| 2022-09-30 | -27.64% |
| 2022-06-30 | -69.19% |
| 2022-03-31 | -52.00% |
| 2021-12-31 | -42.30% |
| 2021-09-30 | -69.02% |
| 2021-06-30 | -134.12% |
| 2021-03-31 | -114.28% |
| 2020-12-31 | -92.23% |
| 2020-09-30 | -143.00% |
| 2020-06-30 | -169.23% |
| 2020-03-31 | -141.81% |
| 2019-12-31 | -265.79% |
| 2019-09-30 | -181.59% |
| 2019-06-30 | -119.19% |
| 2019-03-31 | -96.86% |
| 2018-12-31 | -63.69% |
| 2018-09-30 | -47.39% |
| 2018-06-30 | -37.82% |
| 2018-03-31 | -33.28% |
| 2017-12-31 | -68.84% |
| 2017-09-30 | -65.91% |
| 2017-06-30 | -52.50% |
| 2017-03-31 | -35.20% |
| 2016-09-30 | -215.19% |
| 2016-06-30 | -177.05% |
| 2016-03-31 | -137.33% |
| 2015-12-31 | -108.82% |
| 2015-09-30 | -83.96% |
| 2015-06-30 | -83.08% |
| 2015-03-31 | -74.67% |
| 2014-12-31 | -131.70% |
| 2014-09-30 | -77.49% |
| 2014-06-30 | -60.00% |
| 2014-03-31 | -143.24% |
| 2013-12-31 | -106.57% |
